

Matthias Schwab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7173472/publications.pdf>

Version: 2024-02-01

211
papers

19,174
citations

14655

66
h-index

18130

120
g-index

222
all docs

222
docs citations

222
times ranked

21910
citing authors

#	ARTICLE	IF	CITATIONS
1	Two experts and a newbie: [18F]PARPi vs [18F]FTT vs [18F]FPyPARPâ€”a comparison of PARP imaging agents. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 834-846.	6.4	10
2	Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC. <i>World Journal of Urology</i> , 2022, 40, 739-746.	2.2	5
3	How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	3
4	Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model. <i>Cancers</i> , 2022, 14, 1158.	3.7	6
5	Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	32
6	Physiologicallyâ€”based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 494-511.	2.5	16
7	Development and Experimental Validation of Regularized Machine Learning Models Detecting New, Structurally Distinct Activators of PXR. <i>Cells</i> , 2022, 11, 1253.	4.1	2
8	(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 511.	2.5	3
9	Molybdenum Cofactor Catabolism Unravels the Physiological Role of the Drug Metabolizing Enzyme Thiopurine Sâ€”Methyltransferase. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 808-816.	4.7	5
10	CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL. <i>Leukemia</i> , 2022, 36, 2050-2063.	7.2	5
11	Nicotinamideâ€”methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, .	4.0	20
12	Hepatic Expression of the Na ⁺ -Taurocholate Cotransporting Polypeptide Is Independent from Genetic Variation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7468.	4.1	6
13	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2C19</i> and Proton Pump Inhibitor Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1417-1423.	4.7	157
14	Physiologically Based Precision Dosing Approach for Drugâ€”Drugâ€”Gene Interactions: A Simvastatin Network Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 201-211.	4.7	23
15	Stereoselective quantification of phase 1 and 2 metabolites of clomiphene in human plasma and urine. <i>Talanta</i> , 2021, 221, 121658.	5.5	6
16	Nelfinavir and Its Active Metabolite M8 Are Partial Agonists and Competitive Antagonists of the Human Pregnane X Receptor. <i>Molecular Pharmacology</i> , 2021, 99, 184-196.	2.3	6
17	Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins. <i>British Journal of Pharmacology</i> , 2021, 178, 1459-1474.	5.4	7
18	Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. <i>Pharmaceuticals</i> , 2021, 14, 115.	3.8	4

#	ARTICLE	IF	CITATIONS
19	Repurposing Riociguat for Treatment of Refractory Angina Resulting From Coronary Spasm. <i>JACC: Case Reports</i> , 2021, 3, 392-396.	0.6	8
20	Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters. <i>Pharmaceutics</i> , 2021, 13, 369.	4.5	14
21	No association of genetic variants in TLR4, TNF- α , IL10, IFN- γ , and IL37 in cytomegalovirus-positive renal allograft recipients with active CMV infection—Subanalysis of the prospective randomised VIPP study. <i>PLoS ONE</i> , 2021, 16, e0246118.	2.5	1
22	Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups. <i>Cancers</i> , 2021, 13, 2432.	3.7	1
23	A call to caution when hydroxychloroquine is given to elderly patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 106, 265-268.	3.3	1
24	Data-driven personalization of a physiologically based pharmacokinetic model for caffeine: A systematic assessment. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 782-793.	2.5	13
25	Identification and characterization of novel splice variants of human farnesoid X receptor. <i>Archives of Biochemistry and Biophysics</i> , 2021, 705, 108893.	3.0	3
26	External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease. <i>Pharmaceutics</i> , 2021, 13, 1368.	4.5	13
27	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	9.4	110
28	Genetic and Epigenetic Regulation of Organic Cation Transporters. <i>Handbook of Experimental Pharmacology</i> , 2021, 266, 81-100.	1.8	8
29	Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 6221.	3.7	1
30	Variability and Heritability of Thiamine Pharmacokinetics With Focus on OCT1 Effects on Membrane Transport and Pharmacokinetics in Humans. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 628-638.	4.7	18
31	Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 227-237.	4.7	23
32	Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 57-61.	4.7	42
33	CCI52 sensitizes tumors to 6-mercaptopurine and inhibits MYCN-amplified tumor growth. <i>Biochemical Pharmacology</i> , 2020, 172, 113770.	4.4	2
34	Clinically Relevant OATP2B1 Inhibitors in Marketed Drug Space. <i>Molecular Pharmaceutics</i> , 2020, 17, 488-498.	4.6	9
35	Prevalence of a First-Degree Relative With Colorectal Cancer and Uptake of Screening Among Persons 40 to 54 Years Old. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2535-2543.e3.	4.4	8
36	Hypertonicity-Affected Genes Are Differentially Expressed in Clear Cell Renal Cell Carcinoma and Correlate with Cancer-Specific Survival. <i>Cancers</i> , 2020, 12, 6.	3.7	13

#	ARTICLE	IF	CITATIONS
37	Optimized protocol for metabolomic and lipidomic profiling in formalin-fixed paraffin-embedded kidney tissue by LC-MS. <i>Analytica Chimica Acta</i> , 2020, 1134, 125-135.	5.4	15
38	SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells. <i>Cell Reports</i> , 2020, 32, 108184.	6.4	19
39	Modulating endothelial adhesion and migration impacts stem cell therapies efficacy. <i>EBioMedicine</i> , 2020, 60, 102987.	6.1	10
40	Metabolic Drug Response Phenotyping in Colorectal Cancer Organoids by LC-QTOF-MS. <i>Metabolites</i> , 2020, 10, 494.	2.9	18
41	Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. <i>Scientific Reports</i> , 2020, 10, 12457.	3.3	12
42	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 131-144.	1.5	26
43	Cell motility and migration as determinants of stem cell efficacy. <i>EBioMedicine</i> , 2020, 60, 102989.	6.1	26
44	Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study. <i>Pharmacogenomics</i> , 2020, 21, 325-335.	1.3	21
45	Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 322-331.	2.5	54
46	The cytosolic isoform of glutaredoxin 2 promotes cell migration and invasion. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129599.	2.4	7
47	Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. <i>Pharmaceutics</i> , 2020, 12, 578.	4.5	30
48	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 661-670.	4.7	17
49	Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients. <i>International Journal of Cancer</i> , 2020, 146, 2475-2487.	5.1	20
50	β -Adrenergic Receptor in Liver Fibrosis: Implications for the Adrenoblocker Mesedin. <i>Cells</i> , 2020, 9, 456.	4.1	10
51	Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. <i>Genome Medicine</i> , 2020, 12, 32.	8.2	32
52	A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1398-1407.	4.7	19
53	Tamoxifen Pharmacogenetics and Metabolism: The Same Is Not the Same. <i>Journal of Clinical Oncology</i> , 2019, 37, 1981-1982.	1.6	16
54	Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease. <i>Cells</i> , 2019, 8, 595.	4.1	50

#	ARTICLE	IF	CITATIONS
55	Development of the <sc>PG</sc>â€œPassport: A Panel of Actionable Germline Genetic Variants for Preâ€œmptive Pharmacogenetic Testing. Clinical Pharmacology and Therapeutics, 2019, 106, 866-873.	4.7	73
56	Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genetics in Medicine, 2019, 21, 2145-2150.	2.4	72
57	Ten years of Genome Medicine. Genome Medicine, 2019, 11, 7.	8.2	11
58	Physiologicallyâ€œBased Pharmacokinetic Models for <sc>CYP</sc>1A2 Drugâ€œDrug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 296-307.	2.5	27
59	Pharmacogene Variation Consortium Gene Introduction: <i><sc>NUDT15</sc></i>. Clinical Pharmacology and Therapeutics, 2019, 105, 1091-1094.	4.7	45
60	Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on <i><sc>TPMT</sc></i> and <i><sc>NUDT</sc>15</i> Genotypes: 2018 Update. Clinical Pharmacology and Therapeutics, 2019, 105, 1095-1105.	4.7	428
61	A Web-based survey among adults aged 40â€œ54 years was time effective and yielded stable response patterns. Journal of Clinical Epidemiology, 2019, 105, 10-18.	5.0	7
62	Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin. European Urology Focus, 2019, 5, 608-618.	3.1	35
63	Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy. Clinical and Translational Science, 2018, 11, 352-364.	3.1	90
64	Sex-dimorphic acceleration of pericardial, subcutaneous, and plasma lipid increase in offspring of poorly nourished baboons. International Journal of Obesity, 2018, 42, 1092-1096.	3.4	17
65	Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs. Epilepsy Research, 2018, 141, 83-89.	1.6	9
66	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2D6</i> and Tamoxifen Therapy. Clinical Pharmacology and Therapeutics, 2018, 103, 770-777.	4.7	244
67	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end pointsâ€œRationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	2.7	24
68	Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood, 2018, 131, 2466-2474.	1.4	43
69	Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. Hepatology, 2018, 67, 1609-1619.	7.3	83
70	Validation of a high-performance liquid chromatography method for thiopurine S-methyltransferase activity in whole blood using 6-mercaptopurine as substrate. Clinical Chemistry and Laboratory Medicine, 2018, 56, 803-809.	2.3	3
71	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology and Therapeutics, 2018, 103, 210-216.	4.7	407
72	Systematic Review of Variations in Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis from Colorectal Cancer. Journal of Clinical Medicine, 2018, 7, 567.	2.4	62

#	ARTICLE	IF	CITATIONS
73	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2746-2755.	4.1	53
74	Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 3181-3193.	5.1	40
75	Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. <i>BMC Medicine</i> , 2018, 16, 108.	5.5	11
76	Neuroprotective, Neurogenic, and Amyloid Beta Reducing Effect of a Novel Alpha 2-Adrenoblocker, Mesedin, on Astroglia and Neuronal Progenitors upon Hypoxia and Glutamate Exposure. <i>International Journal of Molecular Sciences</i> , 2018, 19, 9.	4.1	35
77	From hype to reality: data science enabling personalized medicine. <i>BMC Medicine</i> , 2018, 16, 150.	5.5	278
78	Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling. <i>Journal of Proteome Research</i> , 2018, 17, 3039-3049.	3.7	13
79	The fruit fly <i>Drosophila melanogaster</i> as an innovative preclinical ADME model for solute carrier membrane transporters, with consequences for pharmacology and drug therapy. <i>Drug Discovery Today</i> , 2018, 23, 1746-1760.	6.4	10
80	The importance of drug transporter characterization to precision medicine. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 361-365.	3.3	9
81	Ligand-dependent and -independent regulation of human hepatic sphingomyelin phosphodiesterase acid-like 3A expression by pregnane X receptor and crosstalk with liver X receptor. <i>Biochemical Pharmacology</i> , 2017, 136, 122-135.	4.4	8
82	Maternal nutrient restriction during pregnancy and lactation leads to impaired right ventricular function in young adult baboons. <i>Journal of Physiology</i> , 2017, 595, 4245-4260.	2.9	34
83	Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters. <i>Epilepsy Research</i> , 2017, 135, 64-70.	1.6	11
84	Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin". <i>Science Translational Medicine</i> , 2017, 9, .	12.4	4
85	Open letter on access to the BIA 10-2474 clinical trial data. <i>Lancet</i> , The, 2017, 389, 156.	13.7	11
86	Comprehensive Metabolomic and Lipidomic Profiling of Human Kidney Tissue: A Platform Comparison. <i>Journal of Proteome Research</i> , 2017, 16, 933-944.	3.7	41
87	Translational learning from clinical studies predicts drug pharmacokinetics across patient populations. <i>Npj Systems Biology and Applications</i> , 2017, 3, 11.	3.0	14
88	Pharmacokinetics and pharmacodynamics of thiopurines in an in vitro model of human hepatocytes: Insights from an innovative mass spectrometry assay. <i>Chemico-Biological Interactions</i> , 2017, 275, 189-195.	4.0	3
89	Selective p38 MAP kinase/MAPK14 inhibition in enzymatically modified LDL-stimulated human monocytes: implications for atherosclerosis. <i>FASEB Journal</i> , 2017, 31, 674-686.	0.5	29
90	Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen. <i>Frontiers in Pharmacology</i> , 2017, 8, 582.	3.5	52

#	ARTICLE	IF	CITATIONS
91	p110 ³ /r Double-Deficiency Induces Eosinophilia and IgE Production but Protects from OVA-Induced Airway Inflammation. PLoS ONE, 2016, 11, e0159310.	2.5	3
92	Comparison of Different Risk Classification Systems in 558 Patients with Gastrointestinal Stromal Tumors after R0-Resection. Frontiers in Pharmacology, 2016, 7, 504.	3.5	25
93	Association of <i>CYP2C19</i> and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. British Journal of Clinical Pharmacology, 2016, 81, 1142-1152.	2.4	18
94	From genomic medicine to precision medicine: highlights of 2015. Genome Medicine, 2016, 8, 12.	8.2	32
95	First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. Journal of Hepatology, 2016, 65, 483-489.	3.7	187
96	Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. Journal of Hepatology, 2016, 65, 490-498.	3.7	321
97	Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. Archives of Toxicology, 2016, 90, 1555-1584.	4.2	54
98	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. European Journal of Cancer, 2016, 65, 91-101.	2.8	262
99	Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Scientific Reports, 2016, 6, 29930.	3.3	29
100	A phosphotyrosine switch regulates organic cation transporters. Nature Communications, 2016, 7, 10880.	12.8	100
101	Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. Trends in Pharmacological Sciences, 2016, 37, 904-932.	8.7	72
102	Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. Genome Medicine, 2016, 8, 119.	8.2	10
103	PDK1 Determines Collagen-Dependent Platelet Ca ²⁺ Signaling and Is Critical to Development of Ischemic Stroke In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1507-1516.	2.4	29
104	Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPAR α in primary human hepatocytes. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 1218-1227.	1.9	67
105	Achieving the World Health Organization's vision for clinical pharmacology. British Journal of Clinical Pharmacology, 2016, 81, 223-227.	2.4	13
106	NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nature Genetics, 2016, 48, 367-373.	21.4	389
107	Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clinical Pharmacokinetics, 2016, 55, 507-524.	3.5	52
108	Enzymatically Modified Low-Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease. Journal of the American Heart Association, 2015, 4, e002156.	3.7	10

#	ARTICLE	IF	CITATIONS
109	Peroxisome proliferator-activated receptor alpha, PPAR α , directly regulates transcription of cytochrome P450 CYP2C8. <i>Frontiers in Pharmacology</i> , 2015, 6, 261.	3.5	29
110	In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. <i>Nature Biotechnology</i> , 2015, 33, 584-586.	17.5	113
111	Inflammation-Associated MicroRNA-130b Down-Regulates Cytochrome P450 Activities and Directly Targets CYP2C9. <i>Drug Metabolism and Disposition</i> , 2015, 43, 884-888.	3.3	69
112	Role of ABC Transporters in Fluoropyrimidine-Based Chemotherapy Response. <i>Advances in Cancer Research</i> , 2015, 125, 217-243.	5.0	43
113	Data collection as a barrier to personalized medicine. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 68-71.	8.7	36
114	A common variant mapping to CACNA1A is associated with susceptibility to exfoliation syndrome. <i>Nature Genetics</i> , 2015, 47, 387-392.	21.4	97
115	Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na ⁺ -taurocholate cotransporting polypeptide inhibitor. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 6815-6825.	3.7	35
116	Survival Prediction of Clear Cell Renal Cell Carcinoma Based on Gene Expression Similarity to the Proximal Tubule of the Nephron. <i>European Urology</i> , 2015, 68, 1016-1020.	1.9	55
117	Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST). <i>BMC Cancer</i> , 2015, 15, 57.	2.6	39
118	Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. <i>Clinical Pharmacokinetics</i> , 2015, 54, 709-735.	3.5	207
119	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2015, 16, 1639-1650.	10.7	277
120	The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPAR α -tr, autonomously regulates proliferative and pro-inflammatory genes. <i>BMC Cancer</i> , 2015, 15, 488.	2.6	31
121	Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. <i>Archives of Toxicology</i> , 2015, 89, 2089-2103.	4.2	86
122	MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma. <i>Oncotarget</i> , 2015, 6, 30615-30627.	1.8	24
123	Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy. <i>Review of Diabetic Studies</i> , 2015, 12, 363-376.	1.3	12
124	Differential Expression of Drug Uptake and Efflux Transporters in Japanese Patients with Hepatocellular Carcinoma. <i>Drug Metabolism and Disposition</i> , 2014, 42, 2033-2040.	3.3	38
125	Intranasal Delivery of Bone Marrow-Derived Mesenchymal Stem Cells, Macrophages, and Microglia to the Brain in Mouse Models of Alzheimer's and Parkinson's Disease. <i>Cell Transplantation</i> , 2014, 23, 123-139.	2.5	114
126	Interplay between Endothelin and Erythropoietin in Astroglia: The Role in Protection against Hypoxia. <i>International Journal of Molecular Sciences</i> , 2014, 15, 2858-2875.	4.1	8

#	ARTICLE	IF	CITATIONS
127	Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1). <i>Clinical Cancer Research</i> , 2014, 20, 985-994.	7.0	54
128	Genetic Biomarkers in Epilepsy. <i>Neurotherapeutics</i> , 2014, 11, 324-333.	4.4	26
129	Mechanisms and assessment of statin-related muscular adverse effects. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 454-466.	2.4	88
130	Solute carrier transporter and drug-related nephrotoxicity: the impact of proximal tubule cell models for preclinical research. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 395-408.	3.3	40
131	TCF-1-mediated Wnt signaling regulates Paneth cell innate immune defense effectors HD-5 and -6: implications for Crohn's disease. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G487-G498.	3.4	41
132	Simultaneous quantification of mefloquine (+)- and (âˆ’)-enantiomers and the carboxy metabolite in dried blood spots by liquid chromatography/tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 968, 32-39.	2.3	21
133	2012 highlights in translational 'omics. <i>Genome Medicine</i> , 2013, 5, 10.	8.2	7
134	Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. <i>Genome Medicine</i> , 2013, 5, 1.	8.2	198
135	<i>ABCC11</i> /MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. <i>Pharmacogenomics</i> , 2013, 14, 1433-1448.	1.3	21
136	Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 126-135.	8.7	150
137	Omics and Drug Response. <i>Annual Review of Pharmacology and Toxicology</i> , 2013, 53, 475-502.	9.4	130
138	Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, 138, 103-141.		2,924
139	Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 349-365.	3.1	22
140	DNA Methylation of the <i>SLC16A3</i> Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome. <i>Clinical Cancer Research</i> , 2013, 19, 5170-5181.	7.0	90
141	Direct Transcriptional Regulation of Human Hepatic Cytochrome P450 3A4 (CYP3A4) by Peroxisome Proliferator-Activated Receptor Alpha (PPAR α). <i>Molecular Pharmacology</i> , 2013, 83, 709-718.	2.3	88
142	The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1906-1913.	3.3	8
143	Mucosal Improvement in Patients With Moderate to Severe Postoperative Endoscopic Recurrence of Crohn's Disease and Azathioprine Metabolite Levels. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 590-598.	1.9	17
144	Nomenclature for alleles of the thiopurine methyltransferase gene. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 242-248.	1.5	104

#	ARTICLE	IF	CITATIONS
145	Age-Dependent Astroglial Vulnerability to Hypoxia and Glutamate: The Role for Erythropoietin. PLoS ONE, 2013, 8, e77182.	2.5	30
146	Simultaneous Quantification of Eleven Thiopurine Nucleotides by Liquid Chromatography-Tandem Mass Spectrometry. Analytical Chemistry, 2012, 84, 1294-1301.	6.5	52
147	PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo. Clinical Pharmacology and Therapeutics, 2012, 91, 1044-1052.	4.7	131
148	Pharmacogenomics: a key component of personalized therapy. Genome Medicine, 2012, 4, 93.	8.2	27
149	Organic Anion Transporters and Their Implications in Pharmacotherapy. Pharmacological Reviews, 2012, 64, 421-449.	16.0	105
150	Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells. Human Mutation, 2012, 33, 750-762.	2.5	16
151	Mammalian MATE (SLC47A) transport proteins: impact on efflux of endogenous substrates and xenobiotics. Drug Metabolism Reviews, 2011, 43, 499-523.	3.6	59
152	Organic Cation Transporters (OCTs, MATEs), In Vitro and In Vivo Evidence for the Importance in Drug Therapy. Handbook of Experimental Pharmacology, 2011, , 105-167.	1.8	312
153	DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Medicine, 2011, 3, 82.	8.2	124
154	Therapeutic Efficacy of Intranasally Delivered Mesenchymal Stem Cells in a Rat Model of Parkinson Disease. Rejuvenation Research, 2011, 14, 3-16.	1.8	225
155	Developmental Pharmacokinetics. Handbook of Experimental Pharmacology, 2011, 205, 51-75.	1.8	83
156	Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis. Frontiers in Pharmacology, 2011, 2, 41.	3.5	41
157	The earwax-associated SNP c.538G>A (G180R) in ABCC11 is not associated with breast cancer risk in Europeans. Breast Cancer Research and Treatment, 2011, 129, 993-999.	2.5	20
158	Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs). PLoS ONE, 2011, 6, e22163.	2.5	140
159	Determination of 6-Thioguanosine Diphosphate and Triphosphate and Nucleoside Diphosphate Kinase Activity in Erythrocytes: Novel Targets for Thiopurine Therapy?. Therapeutic Drug Monitoring, 2010, 32, 119-128.	2.0	20
160	Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver. Frontiers in Pharmacology, 2010, 1, 129.	3.5	81
161	Organic cation transporter pharmacogenomics and drug-drug interaction. Expert Review of Clinical Pharmacology, 2010, 3, 707-711.	3.1	10
162	ADME Pharmacogenetics and Its Impact on Drug-Drug Interactions. , 2010, , 51-74.		3

#	ARTICLE	IF	CITATIONS
163	Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. <i>Hepatology</i> , 2009, 50, 1227-1240.	7.3	316
164	Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 760-774.	9.1	127
165	HETEROGENEITY OF DRUG RESPONSES AND INDIVIDUALIZATION OF THERAPY. , 2009, , 225-238.		1
166	Genetic Variants of Wnt Transcription Factor TCF-4 (TCF7L2) Putative Promoter Region Are Associated with Small Intestinal Crohn's Disease. <i>PLoS ONE</i> , 2009, 4, e4496.	2.5	125
167	Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 392, 1093-1108.	3.7	510
168	Highly Multiplexed Genotyping of Thiopurine S-Methyltransferase Variants Using MALDI-TOF Mass Spectrometry: Reliable Genotyping in Different Ethnic Groups. <i>Clinical Chemistry</i> , 2008, 54, 1637-1647.	3.2	103
169	Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 545-568.	3.3	114
170	Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the Thiopurine S-Methyltransferase Gene. , 2008, , 173-201.		1
171	Differential Effects of Targeted Disruption of Thiopurine Methyltransferase on Mercaptopurine and Thioguanine Pharmacodynamics. <i>Cancer Research</i> , 2007, 67, 4965-4972.	0.9	39
172	Monitoring of Thiopurine Methyltransferase Activity in Postsurgical Patients With Crohn's Disease During 1 Year of Treatment With Azathioprine or Mesalazine. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 1-5.	2.0	41
173	Thiopurine Treatment in Inflammatory Bowel Disease. <i>Clinical Pharmacokinetics</i> , 2007, 46, 187-208.	3.5	145
174	The Authors??? Reply. <i>Clinical Pharmacokinetics</i> , 2007, 46, 805.	3.5	0
175	Transport studies with 5-aminosalicylate. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 871-875.	1.9	13
176	Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) â€” association with decreased enzyme function. <i>Human Mutation</i> , 2006, 27, 976-976.	2.5	55
177	GSTP1 and MDR1 Genotypes and Central Nervous System Relapse in Childhood Acute Lymphoblastic Leukemia. <i>International Journal of Hematology</i> , 2005, 81, 39-44.	1.6	47
178	Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 267-279.	13.7	121
179	DETERMINANTS OF NON-RESPONSE IN HELICOBACTER PYLORI ERADICATION TRIALS. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1471-1471.	2.8	1
180	Thiopurine S-methyltransferase as a target for drug interactions. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 395-398.	1.9	24

#	ARTICLE	IF	CITATIONS
181	Thiopurine Methyltransferase (<EMPH TYPE="ITAL">TPMT</EMPH>) Genotype and Early Treatment Response to Mercaptopurine in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2005, 293, 1485.	7.4	248
182	ABCB1 Genotype of the Donor but Not of the Recipient Is a Major Risk Factor for Cyclosporine-Related Nephrotoxicity after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2005, 16, 1501-1511.	6.1	208
183	6-Thioguanosine Diphosphate and Triphosphate Levels in Red Blood Cells and Response to Azathioprine Therapy in Crohn's Disease. Clinical Gastroenterology and Hepatology, 2005, 3, 1007-1014.	4.4	81
184	Mechanisms of Clinical Resistance to Small Molecule Tyrosine Kinase Inhibitors Targeting Oncogenic Tyrosine Kinases. Molecular Diagnosis and Therapy, 2005, 5, 101-112.	3.3	12
185	CYP3A5 Genotype is Associated with Diagnosis of Hypertension in Elderly Patients. Molecular Diagnosis and Therapy, 2005, 5, 191-195.	3.3	36
186	Activating Mutation of the Renal Epithelial Chloride Channel ClC-Kb Predisposing to Hypertension. Hypertension, 2004, 43, 1175-1181.	2.7	97
187	Richtlinie: Labormedizinische Diagnostik bei der Therapie mit TPMT (Thiopurin-S-Methyltransferase)-abhängigen Pharmaka. Guidelines for the laboratory management of thiopurine drug therapy. Das Medizinische Laboratorium, 2004, 28, 477-482.	0.0	2
188	CYP2C19 Polymorphism and Proton Pump Inhibitors. Basic and Clinical Pharmacology and Toxicology, 2004, 95, 2-8.	2.5	138
189	Identification of Budesonide and Prednisone as Substrates of the Intestinal Drug Efflux Pump P-glycoprotein. Inflammatory Bowel Diseases, 2004, 10, 578-583.	1.9	78
190	Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 124-30.	3.0	29
191	CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of. Clinical Pharmacology and Therapeutics, 2004, 76, 201-209.	4.7	93
192	High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics and Genomics, 2004, 14, 429-440.	5.7	391
193	Comprehensive analysis of thiopurine S-methyltransferase phenotype's genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics and Genomics, 2004, 14, 407-417.	5.7	393
194	Clinical Aspects of the MDR1 (ABCB1) Gene Polymorphism. Therapeutic Drug Monitoring, 2004, 26, 180-185.	2.0	170
195	Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics and Genomics, 2004, 14, 309-318.	5.7	104
196	GENETIC POLYMORPHISMS OF THE HUMAN MDR1 DRUG TRANSPORTER. Annual Review of Pharmacology and Toxicology, 2003, 43, 285-307.	9.4	294
197	Population pharmacokinetics of oral busulfan in children. Cancer Chemotherapy and Pharmacology, 2003, 52, 209-216.	2.3	43
198	Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 2003, 38, 978-988.	7.3	426

#	ARTICLE	IF	CITATIONS
199	Sex is a major determinant of CYP3A4 expression in human liver. <i>Hepatology</i> , 2003, 38, 978-988.	7.3	244
200	Association of the P-Glycoprotein Transporter MDR1 C3435T Polymorphism with the Susceptibility to Renal Epithelial Tumors. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1847-1854.	6.1	233
201	Using Trade Names. <i>Archives of Internal Medicine</i> , 2002, 162, 1065.	3.8	27
202	Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 429-436.	5.7	236
203	Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: Consequences for enzyme expression and busulfan conjugation*. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 479-487.	4.7	73
204	Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. <i>Gastroenterology</i> , 2001, 121, 500-501.	1.3	56
205	Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease. <i>Clinical Pharmacokinetics</i> , 2001, 40, 723-751.	3.5	111
206	Frequency of C3435T polymorphism of MDR1 gene in African people. <i>Lancet, The</i> , 2001, 358, 383-384.	13.7	260
207	High-Throughput Genotyping of Thiopurine S-Methyltransferase by Denaturing HPLC. <i>Clinical Chemistry</i> , 2001, 47, 548-555.	3.2	84
208	Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 399-415.	5.7	556
209	Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 69, 169-174.	4.7	628
210	Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis. , 1998, 31, 159-165.		48
211	A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2